06:48:21 Europe / Stockholm

Share price & Turnover

Share price change and turnover during the day of this press release

Subscription

Calendar

2026-02-20 Year-end Report 2025
2025-11-21 Quarterly Report 2025-Q3
2025-08-22 Quarterly Report 2025-Q2
2025-05-22 Quarterly Report 2025-Q1
2025-02-21 Year-end Report 2024
2024-11-21 Quarterly Report 2024-Q3
2024-08-22 Quarterly Report 2024-Q2
2024-05-24 Ex-date Ordinary Dividend ABLI 0.00 SEK
2024-05-23 Quarterly Report 2024-Q1
2024-05-23 Annual General meeting
2024-03-26 Extra General Meeting 2024
2024-02-23 Year-end Report 2023
2023-11-17 Quarterly Report 2023-Q3
2023-08-18 Quarterly Report 2023-Q2
2023-05-23 Quarterly Report 2023-Q1
2023-05-08 Ex-date Ordinary Dividend ABLI 0.00 SEK
2023-05-05 Annual General meeting
2023-03-08 Extra General Meeting 2022
2023-02-24 Year-end Report 2022
2022-11-22 Quarterly Report 2022-Q3
2022-08-19 Quarterly Report 2022-Q2
2022-05-31 Quarterly Report 2022-Q1
2022-05-20 Annual General meeting
2022-04-28 Ex-date Ordinary Dividend ABLI 0.00 SEK
2022-02-22 Year-end Report 2021
2021-11-19 Quarterly Report 2021-Q3
2021-08-19 Quarterly Report 2021-Q2
2021-05-21 Ex-date Ordinary Dividend ABLI 0.00 SEK
2021-05-20 Annual General meeting
2021-05-20 Quarterly Report 2021-Q1
2021-04-29 Extra General Meeting 2021
2021-02-19 Year-end Report 2020
2020-11-20 Quarterly Report 2020-Q3
2020-08-21 Quarterly Report 2020-Q2
2020-05-22 Ex-date Ordinary Dividend ABLI 0.00 SEK
2020-05-20 Quarterly Report 2020-Q1
2020-05-20 Annual General meeting
2020-03-17 Extra General Meeting 2020
2020-02-19 Year-end Report 2019
2019-11-20 Quarterly Report 2019-Q3
2019-08-21 Quarterly Report 2019-Q2
2019-05-21 Quarterly Report 2019-Q1
2019-04-26 Ex-date Ordinary Dividend ABLI 0.00 SEK
2019-04-25 Annual General meeting
2019-02-28 Year-end Report 2018
2019-01-17 Extra General Meeting 2018
2018-11-22 Quarterly Report 2018-Q3
2018-08-21 Quarterly Report 2018-Q2
2018-05-22 Quarterly Report 2018-Q1
2018-04-30 Ex-date Ordinary Dividend ABLI 0.00 SEK
2018-04-27 Annual General meeting
2018-02-20 Year-end Report 2017
2017-11-21 Quarterly Report 2017-Q3
2017-08-17 Quarterly Report 2017-Q2
2017-05-18 Quarterly Report 2017-Q1
2017-04-28 Ex-date Ordinary Dividend ABLI 0.00 SEK
2017-04-27 Annual General meeting
2017-02-21 Year-end Report 2016
2016-11-22 Quarterly Report 2016-Q3
2016-08-18 Quarterly Report 2016-Q2
2016-05-31 Quarterly Report 2016-Q1
2016-04-29 Ex-date Ordinary Dividend ABLI 0.00 SEK
2016-04-28 Annual General meeting
2016-03-31 Extra General Meeting 2016
2016-02-19 Year-end Report 2015
2015-11-18 Quarterly Report 2015-Q3
2015-08-19 Quarterly Report 2015-Q2
2015-05-20 Quarterly Report 2015-Q1
2015-03-31 Ex-date Ordinary Dividend ABLI 0.00 SEK
2015-03-30 Annual General meeting
2015-02-18 Year-end Report 2014
2014-11-19 Quarterly Report 2014-Q3
2014-08-20 Quarterly Report 2014-Q2
2014-05-12 Ex-date Ordinary Dividend ABLI 0.00 SEK
2014-05-09 Quarterly Report 2014-Q1
2014-05-09 Annual General meeting
2014-02-19 Year-end Report 2013
2014-01-21 Analyst Meeting 2014
2013-12-13 Extra General Meeting 2013
2013-11-20 Quarterly Report 2013-Q3
2013-08-23 Quarterly Report 2013-Q2
2013-05-24 Quarterly Report 2013-Q1
2013-03-11 Ex-date Ordinary Dividend ABLI 0.00 SEK
2013-03-08 Annual General meeting
2013-02-05 Year-end Report 2012
2012-10-15 Quarterly Report 2012-Q3
2012-08-21 Quarterly Report 2012-Q2
2012-06-11 Ex-date Ordinary Dividend ABLI 0.00 SEK
2012-06-08 Annual General meeting
2012-05-31 Quarterly Report 2012-Q1
2012-04-02 Extra General Meeting 2012
2012-02-21 Year-end Report 2011
2011-11-22 Quarterly Report 2011-Q3
2011-08-23 Quarterly Report 2011-Q2
2011-06-10 Annual General meeting
2011-05-17 Quarterly Report 2011-Q1
2011-02-22 Year-end Report 2010
2010-11-18 Quarterly Report 2010-Q3
2010-08-19 Quarterly Report 2010-Q2
2010-06-11 Ex-date Ordinary Dividend ABLI 0.00 SEK
2010-05-20 Quarterly Report 2010-Q1
2009-11-19 Quarterly Report 2009-Q3

Description

CountrySweden
ListSmall Cap Stockholm
SectorHealth care
IndustryBiotechnology
Abliva är ett läkemedelsbolag. Bolaget utvecklar läkemedel för behandling av primära mitokondriella sjukdomar. Dessa medfödda, sällsynta och ofta mycket svåra sjukdomar uppstår då cellens energiförsörjare, mitokondrierna, inte fungerar som de ska. Portföljen omfattar projekt i olika skeden och sträcker sig från tidig upptäcktsfas till klinisk fas. Bolaget gick tidigare under namnet NeuroVive Pharmaceutical.
2024-03-27 10:35:00

THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER COUNTRY WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE PREPARED OR REGISTERED OR REQUIRE ANY OTHER ACTIONS TO BE TAKEN, IN ADDITION TO THE REQUIREMENTS UNDER SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has, in connection with the preferential rights issue announced on 22 February 2024, prepared a prospectus (the “Prospectus”) which today has been approved and registered by the Swedish Financial Supervisory Authority.

Publication of Prospectus
The Prospectus has today, 27 March 2024, been approved and registered with the Swedish Financial Supervisory Authority. The Prospectus refers to an invitation to subscribe for shares as a result of the rights issue published in a press release on 22 February 2024 (the “Rights Issue”). The Prospectus, containing complete terms and conditions, instructions and application forms for the Rights issue are available on the Company’s website (www.abliva.com) and on Hagberg & Aneborn Fondkommission’s website (www.hagberganeborn.se). The prospectus will also be available on Finansinspektionen’s website (www.fi.se).

The rights issue in summary

  • Shareholders in Abliva receive one (1) subscription right per share held on the record date of 28 March 2024
  • Eleven (11) subscription rights entitle to subscribe for three (3) new shares
  • The subscription price is SEK 0.16 per share
  • Trading in subscription rights takes place during the period 3 – 12 April 2024
  • The subscription period runs during the period 3 – 17 April 2024

The rights issue is 100 percent covered by subscription and guarantee commitments. Upon full subscription in the Rights Issue, the Company will receive approximately SEK 46 million before transaction costs which is estimated to amount to approximately SEK 6.5 million (of which up to approximately SEK 3.3 million is underwriting fees). For further information on the Rights Issue, please refer to the published prospectus.

Advisors
Hagberg & Aneborn Fondkommission AB is the sole global coordinator and bookrunner in connection with the Rights Issue. Cirio Advokatbyrå AB is legal advisor to Abliva in connection with the Rights Issue.